B. Riley analyst Mayank Mamtani lowered the firm’s price target on Novavax to $11 from $12 and keeps a Buy rating on the shares. The Gavi arbitration dispute being resolved via a five-year $425M payment schedule “removes a key balance sheet overhang earlier/better than investor expectations,” contends the analyst, who also believes the Street is overlooking the positive impact of recent cost-reduction measures and the company’s increased focus on two FY24 priorities.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVAX:
- Novavax (NASDAQ:NVAX) Settles, Shares Blast Up
- Novavax to pay $80M annually to Gavi in settlement for COVID-19 vaccine APA
- Novavax Settles with Gavi, Commits to Equitable Vaccine Pricing
- Novavax Stock (NASDAQ:NVAX): Too Much Bad News Can Fuel a Reversal
- Novavax announces results from Phase 3 trial of R21/Matrix-M malaria
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue